Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on rare diseases affecting bone health and blood vessel function, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer, will engage in a fireside chat on Wednesday, December 4, 2024, from 2:30-2:55pm ET. The presentation will be accessible via live webcast through Inozyme's Investor Relations website section, with a replay available for time.
Inozyme Pharma (Nasdaq: INZY), una società biofarmaceutica in fase clinica focalizzata su malattie rare che riguardano la salute delle ossa e la funzione dei vasi sanguigni, ha annunciato la sua partecipazione alla 36a Conferenza Annuale sulla Salute di Piper Sandler. Matt Winton, Ph.D., Vicepresidente Senior e Chief Operating Officer, parteciperà a una chiacchierata informale mercoledì 4 dicembre 2024, dalle 14:30 alle 14:55 ET. La presentazione sarà accessibile tramite webcast dal vivo attraverso la sezione Relazioni con gli Investitori di Inozyme, con una registrazione disponibile successivamente.
Inozyme Pharma (Nasdaq: INZY), una empresa biofarmacéutica en etapa clínica centrada en enfermedades raras que afectan la salud ósea y la función vascular, ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. Matt Winton, Ph.D., Vicepresidente Senior y Director de Operaciones, participará en una charla informal el miércoles 4 de diciembre de 2024, de 2:30 a 2:55 p.m. ET. La presentación será accesible a través de una transmisión en vivo a través de la sección de Relaciones con Inversores de Inozyme, con una repetición disponible más tarde.
Inozyme Pharma (Nasdaq: INZY)는 뼈 건강과 혈관 기능에 영향을 미치는 희귀 질환에 집중하는 임상 단계의 생명공학 회사로, Piper Sandler 제36회 연례 의료 회의에 참가할 것이라고 발표했습니다. Matt Winton, Ph.D., 수석 부사장 및 운영 책임자는 2024년 12월 4일 수요일 오후 2시 30분부터 2시 55분(ET)까지 대화에 참여할 예정입니다. 발표는 Inozyme의 투자자 관계 웹사이트 섹션을 통해 실시간 웹캐스트로 접근할 수 있으며, 이후 다시 보기도 가능합니다.
Inozyme Pharma (Nasdaq: INZY), une entreprise biopharmaceutique en phase clinique axée sur les maladies rares affectant la santé osseuse et la fonction vasculaire, a annoncé sa participation à la 36e Conférence Annuelle sur la Santé de Piper Sandler. Matt Winton, Ph.D., Vice-Président Senior et Directeur des Opérations, participera à une discussion informelle le mercredi 4 décembre 2024, de 14 h 30 à 14 h 55 HE. La présentation sera accessible par webcast en direct via la section Relations Investisseurs d'Inozyme, avec une rediffusion disponible par la suite.
Inozyme Pharma (Nasdaq: INZY), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf seltene Krankheiten konzentriert, die die Knochengesundheit und die Funktion von Blutgefäßen betreffen, hat seine Teilnahme an der 36. jährlichen Gesundheitskonferenz von Piper Sandler angekündigt. Matt Winton, Ph.D., Senior Vice President und Chief Operating Officer, wird am Mittwoch, den 4. Dezember 2024, von 14:30 bis 14:55 Uhr ET an einem informellen Gespräch teilnehmen. Die Präsentation wird über einen Live-Webcast über den Bereich Investor Relations von Inozyme zugänglich sein, mit einer anschließenden Wiederholung.
- None.
- None.
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 from 2:30-2:55pm ET.
A live webcast of the fireside chat can be accessed from the Investor Relations section of Inozyme’s website under events, where a replay of the event will also be available for a limited time.
About Inozyme Pharma
Inozyme Pharma is a pioneering clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. We are experts in the PPi-Adenosine Pathway, where the ENPP1 enzyme generates inorganic pyrophosphate (PPi), which regulates mineralization, and adenosine, which controls intimal proliferation (the overgrowth of smooth muscle cells inside blood vessels). Disruptions in this pathway impact the levels of these molecules, leading to severe musculoskeletal, cardiovascular, and neurological conditions, including ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and ossification of the posterior longitudinal ligament (OPLL).
Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these molecules. It is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, addressing the significant morbidity and mortality in these devastating diseases.
For more information, please visit https://www.inozyme.com/ or follow Inozyme on LinkedIn, X, and Facebook.
Contacts
Investors:
Inozyme Pharma
Stefan Riley, Senior Director of IR and Corporate Communications
(617) 461-2442
stefan.riley@inozyme.com
Media:
Biongage Communications
Todd Cooper
(617) 840-1637
todd@biongage.com
FAQ
When is Inozyme Pharma (INZY) presenting at the Piper Sandler Healthcare Conference 2024?
Who will represent Inozyme Pharma (INZY) at the Piper Sandler Healthcare Conference?
How can investors watch Inozyme Pharma's (INZY) presentation at the Piper Sandler Conference?
What type of diseases does Inozyme Pharma (INZY) focus on developing treatments for?
